Pharmacokinetics and Changes in Lipid Mediator Profiling after Consumption of Specialized Pro-Resolving Lipid-Mediator-Enriched Marine Oil in Healthy Subjects.
Level 4 - case-series / case-control
Single-arm, uncontrolled experimental pharmacokinetic pilot study in 10 healthy participants
PubMed 38003333 · doi:10.3390/ijms242216143
What was done
Ten healthy subjects were enrolled in an experimental pilot study to evaluate the pharmacokinetics of an oral specialized pro-resolving mediator (SPM)-enriched marine oil emulsion. Each participant ingested a single 6 g dose, and peripheral blood was collected at baseline, 3, 6, 9, 12, and 24 hours post-administration. LC-MS/MS lipid profiling was used to measure temporal changes and basic pharmacokinetic profiles of SPMs and omega-3 fatty acids in both plasma and serum.
What was found
The authors report time-dependent increases in plasma and serum SPM levels and omega-3 levels over the 24-hour period. However, the abstract does not report specific numerical values, pharmacokinetic parameters (such as AUC, Cmax, or Tmax), or statistical confidence intervals.
Why it matters
This study provides proof-of-principle evidence in humans that oral SPM-enriched marine oil is bioavailable and can acutely raise circulating levels of bioactive resolving lipid mediators.
Limits
The study is limited by a very small sample size (n = 10), lack of a control or placebo arm, and an exclusively healthy population. It only assessed a single acute dose over 24 hours, so steady-state kinetics, biological resolution outcomes, and clinical efficacy remain unmeasured.
Cited by
- supports Specialized pro-resolving mediators (SPMs) generated from omega-3 supplementation remain in circulation for 24 hours.